TELO Q1 2023 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$482,938

Net Income

-$482,938

EPS (Diluted)

$-0.02

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$735,739

Free Cash Flow

-$735,739

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$0

Total Liabilities

$0

Stockholders' Equity

-$937,278

Cash & Equivalents

-$1,419

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$482,938	-$63,490	-660.7%
Net Income	-$482,938	-$63,490	-660.7%